- /
- Supported exchanges
- / US
- / EWTX.NASDAQ
Edgewise Therapeutics Inc (EWTX NASDAQ) stock market data APIs
Edgewise Therapeutics Inc Financial Data Overview
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Edgewise Therapeutics Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Edgewise Therapeutics Inc data using free add-ons & libraries
Get Edgewise Therapeutics Inc Fundamental Data
Edgewise Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -189 322 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Edgewise Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-05-07
- EPS/Forecast: -0.4429
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Edgewise Therapeutics Inc News
New
How This Biotech Scored 'A Clear Win' Where Bristol Myers Failed
Cytokinetics stock surged Tuesday on positive results in a key heart disease where its chief rival, Bristol's Camzyos, previously failed. Continue Reading
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., May 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...
Can Myqorzo Drive Growth for Cytokinetics Amid Competition?
Cytokinetics, Incorporated CYTK has entered a pivotal phase following the FDA approval of its first commercial product, Myqorzo (aficamten), for the treatment of symptomatic obstructive hypertrophic c...
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., April 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutic...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.